# Quest Diagnostics Inc (DGX)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/quest-diagnostics-inc/ JSON: https://steadybase.io/company/quest-diagnostics-inc.json Checked Nov 10, 2026. Latest filing read: Oct 23, 2026.

## Company

- Legal name: QUEST DIAGNOSTICS INC
- Ticker: DGX (NYSE)
- SEC CIK: 0001022079
- Industry: Services-Medical Laboratories (SIC 8071)
- Headquarters: Secaucus, NJ
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: questdiagnostics.com
- Investor relations: https://ir.questdiagnostics.com/overview/default.aspx
- LinkedIn: https://www.linkedin.com/company/quest-diagnostics
- Next earnings date: Jan 21, 2027 (estimated from past 8-K timing)

## Key facts

- Revenue: $11.0B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000015/0001022079-26-000015-index.html
- Operating income: $1.6B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000015/0001022079-26-000015-index.html
- Net income: $992.0M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000015/0001022079-26-000015-index.html
- SG&A: $2.0B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000015/0001022079-26-000015-index.html
- Employees: 57,000 as of Feb 26, 2026, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000015/0001022079-26-000015-index.html
- Shares outstanding: 110,019,073 as of Oct 15, 2026 (10-Q filed Oct 23, 2026). Source: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000108/0001022079-26-000108-index.html
- Auditor: Pricewaterhousecoopers LLP, Florham Park, New Jersey, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000015/dgx-20251231.htm

## Business

Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians, and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1022079/000102207926000015/dgx-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $11.0B | $1.6B | $992.0M | $2.0B |
| Dec 31, 2024 | $9.9B | $1.3B | $871.0M | $1.8B |
| Dec 31, 2023 | $9.3B | $1.3B | $854.0M | $1.6B |
| Dec 31, 2022 | $9.9B | $1.4B | $946.0M | $1.9B |
| Dec 31, 2021 | $10.8B | $2.4B | $2.0B | $1.7B |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/quest-diagnostics-inc.json

## Officers and directors

- Jim Davis, Chairman, CEO and President. Source: 8-K filed Oct 22, 2026, https://www.sec.gov/Archives/edgar/data/1022079/000102207926000097/dgx093020268-kex991.htm
- J. E. Davis, CEO and President. Source: Form 4 filed Sep 3, 2026, https://www.sec.gov/Archives/edgar/data/1022079/000159983726000007/0001599837-26-000007-index.htm
- Sam Samad, Executive Vice President & CFO. Source: Form 4 filed Jul 27, 2026, https://www.sec.gov/Archives/edgar/data/1022079/000102207926000081/0001022079-26-000081-index.htm
- Sam A. Samad, Executive Vice President and Chief Financial Officer. LinkedIn: https://linkedin.com/in/ssamad. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1022079/000102207926000015/dgx-20251231.htm
- Michael E. Prevoznik, SVP & General Counsel. LinkedIn: https://linkedin.com/in/michael-prevoznik-397a043. Source: Form 4 filed Aug 31, 2026, https://www.sec.gov/Archives/edgar/data/1022079/000102207926000089/0001022079-26-000089-index.htm
- Mark E. Delaney, SVP & Chief Commercial Officer. LinkedIn: https://linkedin.com/in/mark-delaney-807330168. Source: Form 4 filed Jul 29, 2026, https://www.sec.gov/Archives/edgar/data/1022079/000102207926000087/0001022079-26-000087-index.htm
- Catherine T. Doherty, Executive Vice President. Source: Form 4 filed Mar 6, 2026, https://www.sec.gov/Archives/edgar/data/1022079/000102207926000031/0001022079-26-000031-index.htm
- Michael J. Deppe, SVP, Corp. Controller & CAO. LinkedIn: https://linkedin.com/in/michael-deppe-39b931172. Source: Form 4 filed Mar 6, 2026, https://www.sec.gov/Archives/edgar/data/1022079/000102207926000026/0001022079-26-000026-index.htm
- Subu Ramachandran, SVP, Regional Businesses. Source: Form 3 filed Nov 5, 2026, https://www.sec.gov/Archives/edgar/data/1022079/000102207926000120/0001022079-26-000120-index.htm
- Karthik Kuppusamy, SVP, Clinical Solutions. Source: Form 4 filed Jul 27, 2026, https://www.sec.gov/Archives/edgar/data/1022079/000102207926000086/0001022079-26-000086-index.htm
- Patrick Plewman, SVP for Diagnostic Services. LinkedIn: https://linkedin.com/in/patrickplewman. Source: Form 4 filed Jul 27, 2026, https://www.sec.gov/Archives/edgar/data/1022079/000102207926000083/0001022079-26-000083-index.htm

## Recent 8-K events

- Oct 22, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000097/dgx-20261022.htm
- Oct 22, 2026: Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/1022079/000094787126000941/ss6979200_8k.htm
- Oct 6, 2026: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/1022079/000094787126000922/ss6908054_8k.htm
- Jul 23, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000067/dgx-20260723.htm
- May 21, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000052/dgx-20260520.htm
- May 8, 2026: Item 1.01, Entry into a material definitive agreement; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1022079/000110465926057938/tm2613096d2_8k.htm
- May 1, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1022079/000110465926054141/tm2613096d1_8k.htm
- Apr 21, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000040/dgx-20260421.htm
- Mar 12, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1022079/000094787126000244/ss6056588_8k.htm
- Feb 10, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000005/dgx-20260210.htm

## Insider trades (Form 4)

- Nov 3, 2026: Catherine T. Doherty (Executive Vice President) sold 22,105 shares, about $5.5M. Source: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000122/0001022079-26-000122-index.htm
- Oct 26, 2026: Gary M. Pfeiffer (Director) sold 1,203 shares, about $292,329. Source: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000118/0001022079-26-000118-index.htm
- Sep 1, 2026: J. E. Davis (CEO and President) sold 10,000 shares, about $2.4M. Source: https://www.sec.gov/Archives/edgar/data/1022079/000159983726000007/0001599837-26-000007-index.htm
- Aug 28, 2026: Michael E. Prevoznik (SVP & General Counsel) sold 22,677 shares, about $5.5M. Source: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000089/0001022079-26-000089-index.htm
- Jul 28, 2026: Mark E. Delaney (SVP & Chief Commercial Officer) sold 1,600 shares, about $376,288. Source: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000087/0001022079-26-000087-index.htm
- Jun 4, 2026: Karthik Kuppusamy (SVP, Clinical Solutions) sold 8,147 shares, about $1.6M. Source: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000053/0001022079-26-000053-index.htm
- Jun 1, 2026: J. E. Davis (CEO and President) sold 10,000 shares, about $1.9M. Source: https://www.sec.gov/Archives/edgar/data/1022079/000159983726000005/0001599837-26-000005-index.htm
- Mar 5, 2026: Catherine T. Doherty (EVP, Regional Businesses) sold 5,558 shares, about $1.1M. Source: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000031/0001022079-26-000031-index.htm
- Mar 5, 2026: Michael E. Prevoznik (SVP & General Counsel) sold 3,878 shares, about $799,682. Source: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000029/0001022079-26-000029-index.htm
- Mar 5, 2026: Patrick Plewman (SVP for Diagnostic Services) sold 2,855 shares, about $588,730. Source: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000027/0001022079-26-000027-index.htm
- Mar 4, 2026: Karthik Kuppusamy (SVP, Clinical Solutions) sold 2,628 shares, about $538,372. Source: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000025/0001022079-26-000025-index.htm
- Mar 3, 2026: Catherine T. Doherty (EVP, Regional Businesses) sold 632 shares, about $131,285. Source: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000024/0001022079-26-000024-index.htm
- Mar 3, 2026: Michael E. Prevoznik (SVP & General Counsel) sold 526 shares, about $109,266. Source: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000022/0001022079-26-000022-index.htm
- Mar 3, 2026: Patrick Plewman (SVP for Diagnostic Services) sold 410 shares, about $85,169. Source: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000020/0001022079-26-000020-index.htm
- Mar 2, 2026: J. E. Davis (CEO and President) sold 10,000 shares, about $2.1M. Source: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000021/0001022079-26-000021-index.htm

## What management said

- "We delivered revenue growth of 10% and adjusted EPS growth of over 15% on continued strength across our physician, hospital and consumer channels, complemented by productivity gains from automation and AI" Jim Davis, Chairman, CEO and President (8-K filed Oct 22, 2026). Source: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000097/dgx093020268-kex991.htm

## Latest filings

- 8-K filed Oct 22, 2026: https://www.sec.gov/Archives/edgar/data/1022079/000094787126000941/ss6979200_8k.htm
- 10-K filed Feb 26, 2026: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000015/dgx-20251231.htm
- 10-Q filed Oct 23, 2026: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000108/dgx-20260930.htm
- DEF 14A filed Apr 6, 2026: https://www.sec.gov/Archives/edgar/data/1022079/000114036126013356/ny20064122x1_def14a.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/